If there’s one thing our CEO is good at, it’s stringing shareholders along. Missling has been doing it for years. He knows his cult followers will believe anything he says, make excuses for him when he fails to deliver, and blame phantom forces instead of holding him accountable. The problem is that outside of a handful of loud retail message board longs, professional biotech investors don’t take anything he say at face value.
Market Data 
Markets 
AI
